Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the phase 3 POETYK PSO...

Full description

Saved in:
Bibliographic Details
Published inSkin (Milwood, N.Y.) Vol. 7; no. 2; p. s116
Main Authors Lebwohl, Mark, Egeberg, Alexander, Linaberry, Misti, Hoyt, Kim, Banerjee, Subhashis, Kisa, Renata M., Strober, Bruce
Format Journal Article
LanguageEnglish
Published 13.03.2023
Online AccessGet full text

Cover

Loading…